Prostate Cancer Diagnosis: AUA Guidelines on Use of PSA Biomarkers, MRI and Biopsy Techniques Webcast (2023)

Prostate cancer detection remains one of the most common and most controversial aspects of urological practice. In addition to the complexities around screening and use of PSA, the role of other biomarkers, biopsy techniques such as transperineal biopsy and MRI for targeted biopsy are evolving rapidly. This course is intended for urologists, advanced practice providers and trainees interested in using the most evidence-based methods for optimizing detection of clinically important prostate cancers, while improving patient experience and minimizing complications. The faculty were selected from the AUA Prostate Cancer Detection Guideline panel, and they will emphasize the newly published guidelines. The attendee will explore the continuing controversy of screening for prostate cancer, use of PSA, PSA adjuncts and isoforms, and other blood-, urine- and tissue-based biomarkers for prostate cancer detection. This will lead into a discussion of prostate biopsy, including concepts crucial to reducing morbidity of prostate biopsy and improving patient experience. This course reviews available data regarding biopsy indications and techniques, including a strong emphasis on transperineal prostate biopsy. Additionally, this course fully explores the imperative of having a purposeful approach to biopsy aimed at diagnosing clinically meaningful cancer while minimizing detection of clinically insignificant cancer. We also present the most current information regarding the use of image-guided biopsy techniques, such as MRI-ultrasound fusion guided biopsy. Finally, we will look toward the future of prostate cancer diagnosis, including risk-stratified testing, combination tests, and sequencing of imaging and biomarkers. Overall, the course provides an evidence-based and practical overview of methods to detect and diagnose prostate cancer.

ACKNOWLEDGEMENTS

Independent educational grant support provided by:

  • Astellas
  • AstraZeneca
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Lantheus Medical Imaging
  • Merck & Co., Inc.
  • Pfizer, Inc.

Learning Objectives

At the conclusion of this activity, participants will be able to:

  1. Apply the AUA Guidelines for Prostate Cancer Detection and understand the rationale, evidence, level of evidence, strength of recommendation and applications associated with each statement.
  2. Explain how to maximize the benefits and minimize the harms of prostate cancer detection by carefully selecting patients and by using the necessary tools to detect clinically meaningful prostate cancer, while avoiding unnecessary biopsies and detection of clinically unimportant cancers.
  3. Identify the evidence supporting the use of PSA for early detection of prostate cancer, and apply that evidence to different clinical scenarios, incorporating patient characteristics and preferences.
  4. Discuss the available blood, urine and tissue biomarkers used to enhance detection of higher-grade prostate cancer, the evidence supporting their use and the clinical scenarios in which they are most valuable to be used.
  5. Use MRI and fusion biopsy to enhance the detection of clinically significant prostate cancer.
Course summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Course opens: 
05/03/2023
Course expires: 
05/03/2024
Part of: 
AUA2023 Webcasts
Rating: 
0

FACULTY DISCLOSURES:

NameCompany NameRelationship TypeEnd Date
Daniel Ari Barocas, MDAmbuConsultant or Advisor4/26/2022
 LantheusConsultant or Advisor11/29/2023
 Pacific Edge DiagnosticsConsultant or Advisor11/30/2023
 Optum HealthConsultant or Advisor1/2/2023
 AstellasConsultant or Advisor10/2/2023
 On Target LaboratoryConsultant or AdvisorCurrent
John Thomas Wei, MDSanofiConsultant or Advisor8/15/2021
Sigrid Viktoria Carlsson, PhDNone  
Simpa Samuel Salami, MD, MPHBayer PharmaScientific Study or TrialCurrent
Scott E. Eggener, MDProfound MedicalConsultant or AdvisorCurrent
 janssenMeeting Participant or LecturerCurrent
 InsightecConsultant or AdvisorCurrent
 Francis MedicalMeeting Participant or LecturerCurrent
 LantheusConsultant or AdvisorCurrent

 

EDUCATION COUNCIL DISCLOSURES:

PDF icon Education Council Disclosures_2022.pdf

COI REVIEW WORKGROUP DISCLOSURES:

PDF iconCOI Review Work Group Disclosures_2023_0.pdf

 

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by view the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Estimated time to complete this activity: 2.00 hours

Release Date: May, 2023
Expiration Date: May, 2024

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 2.00 AMA PRA Category 1 Credit™
  • 2.00 Non-Physician Participation
Please login or register to take this course.